KRAS and kidney cancer: We observed that the high-risk group had a higher KRAS mRNA level than the low-risk group, and the high-risk group presented worse OS outcomes in lung cancer, ovarian cancer, kidney cancer, colon cancer, and stomach cancer (Figure 8, Supplementary Figures S3 and S4).